In response to several media inquiries, Dr. Hala Sleiman, General Manager of Merck in the Near East region, emphasized that as part of the global efforts to investigate potential therapeutics for COVID-19 and support of independent research, Merck has donated 290,000 units of its interferon beta-1a (Rebif®) to the World Health Organization (WHO) for use in their global SOLIDARITY trial. The SOLIDARITY trial investigates several potential therapeutics for the treatment of COVID-19 and currently has received expressions of interest from over 70 countries.
Dr. Sleiman confirmed that Lebanon has participated in this trial led by the WHO for the treatment of COVID-19 patients. In the clinical trial, the drug Rebif® «interferon beta-1a» is one of several drugs that are being studied to know the extent of the drugs’ ability to combat the infection and to improve patient outcomes. As a company dedicated to human progress and to making a lasting difference on patients’ lives, Merck is fully committed to contributing to solutions related to global health crises such as COVID-19.
Rebif® (interferon beta-1a, solution for subcutaneous injection in pre-filled syringe) is indicated for the treatment of relapsing multiple sclerosis. To date, Rebif® is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.
Dr. Hala Sleiman reiterated, “We continue to work closely with global and national health authorities to respond to the needs of patients impacted by COVID-19”.
